Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 8Leukemia, Myeloid, Chronic-Phase 7Burkitt Lymphoma 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma 3Philadelphia Chromosome 2Pancreatic Neoplasms 2Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1

Interventions

ruxolitinib 23Cyclophosphamide 13Whole-Body Irradiation 10Tacrolimus 9Mycophenolic Acid 9fludarabine phosphate 8fludarabine 8Stem Cell Transplantation 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Busulfan 5Azacitidine 5navitoclax 4Sirolimus 4Melphalan 4Biopsy 4luspatercept 3fedratinib 3Methotrexate 3Cyclosporine 3venetoclax 2selinexor 2parsaclisib 2letermovir 2itacitinib 2bomedemstat 2Injections 2INCB057643 2INCB039110 2Hematopoietic Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × Dasatinib × 1 year × Clear all
NCT00255346 2025-12-30

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 13 charts
MyeloidOther hematologic neoplasm

Leukemia, Mastocytosis, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡